Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 165.00 | |
5 mg | In stock | $ 413.00 | |
10 mg | In stock | $ 689.00 | |
25 mg | In stock | $ 1,490.00 | |
50 mg | In stock | $ 1,980.00 | |
100 mg | In stock | $ 2,500.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 473.00 |
Description | Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer. |
In vitro | Ralaniten triacetate (EPI-506) is a highly specific small molecule targeting the N-terminal domain (NTD) of the androgen receptor (AR). It is commonly used in research on metastatic castration-resistant prostate cancer (mCRPC), where resistance to androgen deprivation therapy has developed[2]. |
Synonyms | EPI-506 |
Molecular Weight | 521.00 |
Formula | C27H33ClO8 |
CAS No. | 1637573-04-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (153.55 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ralaniten triacetate 1637573-04-6 Endocrinology/Hormones Androgen Receptor Ralaniten EPI-506 inhibitor inhibit